Cargando…
Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
SOX1 antibodies (SOX1-abs) are associated with paraneoplastic neurological syndromes (PNS) and small cell lung cancer (SCLC). In many clinical laboratories SOX1-abs are determined by commercial line blots without confirmation by cell-based assay (CBA) with HEK293 cells expressing SOX1. However, the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191251/ https://www.ncbi.nlm.nih.gov/pubmed/37207233 http://dx.doi.org/10.3389/fimmu.2023.1173484 |
_version_ | 1785043423176163328 |
---|---|
author | Arnaldos-Pérez, Cristina Vilaseca, Andreu Naranjo, Laura Sabater, Lidia Dalmau, Josep Ruiz-García, Raquel Graus, Francesc |
author_facet | Arnaldos-Pérez, Cristina Vilaseca, Andreu Naranjo, Laura Sabater, Lidia Dalmau, Josep Ruiz-García, Raquel Graus, Francesc |
author_sort | Arnaldos-Pérez, Cristina |
collection | PubMed |
description | SOX1 antibodies (SOX1-abs) are associated with paraneoplastic neurological syndromes (PNS) and small cell lung cancer (SCLC). In many clinical laboratories SOX1-abs are determined by commercial line blots without confirmation by cell-based assay (CBA) with HEK293 cells expressing SOX1. However, the diagnostic yield of commercial line blots is low and the accessibility to the CBA, that is not commercially available, limited. Here, we evaluated if the addition of the band intensity data of the line blot and the immunoreactivity in a tissue-based assay (TBA) improve the diagnostic performance of the line blot. We examined serum of 34 consecutive patients with adequate clinical information that tested positive for SOX1-abs in a commercial line blot. Samples were also assessed by TBA and CBA. SOX1-abs were confirmed by CBA in 17 (50%) patients, all (100%) had lung cancer (SCLC in 16) and 15/17 (88%) had a PNS. In the remaining 17 patients the CBA was negative and none had PNS associated with lung cancer. TBA was assessable in 30/34 patients and SOX1-abs reactivity was detected in 15/17 (88%) with positive and in 0/13 (0%) with negative CBA. Only 2 (13%) of the 15 TBA-negative patients were CBA-positive. The frequency of TBA-negative but CBA-positive increased from 10% (1/10) when the band intensity of the line blot was weak to 20% (1/5) in patients with a moderate or strong intensity band. Confirmation by CBA should be mandatory for samples (56% in this series) not assessable (4/34; 12%) or negative in the TBA (15/34; 44%). |
format | Online Article Text |
id | pubmed-10191251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101912512023-05-18 Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies Arnaldos-Pérez, Cristina Vilaseca, Andreu Naranjo, Laura Sabater, Lidia Dalmau, Josep Ruiz-García, Raquel Graus, Francesc Front Immunol Immunology SOX1 antibodies (SOX1-abs) are associated with paraneoplastic neurological syndromes (PNS) and small cell lung cancer (SCLC). In many clinical laboratories SOX1-abs are determined by commercial line blots without confirmation by cell-based assay (CBA) with HEK293 cells expressing SOX1. However, the diagnostic yield of commercial line blots is low and the accessibility to the CBA, that is not commercially available, limited. Here, we evaluated if the addition of the band intensity data of the line blot and the immunoreactivity in a tissue-based assay (TBA) improve the diagnostic performance of the line blot. We examined serum of 34 consecutive patients with adequate clinical information that tested positive for SOX1-abs in a commercial line blot. Samples were also assessed by TBA and CBA. SOX1-abs were confirmed by CBA in 17 (50%) patients, all (100%) had lung cancer (SCLC in 16) and 15/17 (88%) had a PNS. In the remaining 17 patients the CBA was negative and none had PNS associated with lung cancer. TBA was assessable in 30/34 patients and SOX1-abs reactivity was detected in 15/17 (88%) with positive and in 0/13 (0%) with negative CBA. Only 2 (13%) of the 15 TBA-negative patients were CBA-positive. The frequency of TBA-negative but CBA-positive increased from 10% (1/10) when the band intensity of the line blot was weak to 20% (1/5) in patients with a moderate or strong intensity band. Confirmation by CBA should be mandatory for samples (56% in this series) not assessable (4/34; 12%) or negative in the TBA (15/34; 44%). Frontiers Media S.A. 2023-05-03 /pmc/articles/PMC10191251/ /pubmed/37207233 http://dx.doi.org/10.3389/fimmu.2023.1173484 Text en Copyright © 2023 Arnaldos-Pérez, Vilaseca, Naranjo, Sabater, Dalmau, Ruiz-García and Graus https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Arnaldos-Pérez, Cristina Vilaseca, Andreu Naranjo, Laura Sabater, Lidia Dalmau, Josep Ruiz-García, Raquel Graus, Francesc Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies |
title | Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies |
title_full | Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies |
title_fullStr | Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies |
title_full_unstemmed | Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies |
title_short | Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies |
title_sort | algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with sox1 antibodies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191251/ https://www.ncbi.nlm.nih.gov/pubmed/37207233 http://dx.doi.org/10.3389/fimmu.2023.1173484 |
work_keys_str_mv | AT arnaldosperezcristina algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies AT vilasecaandreu algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies AT naranjolaura algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies AT sabaterlidia algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies AT dalmaujosep algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies AT ruizgarciaraquel algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies AT grausfrancesc algorithmtoimprovethediagnosisofparaneoplasticneurologicalsyndromesassociatedwithsox1antibodies |